Publication Date
5-1-2022
Journal
JPGN Reports
DOI
10.1097/PG9.0000000000000183
PMID
37168909
PMCID
PMC10158451
PubMedCentral® Posted Date
3-17-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Abstract
Sirolimus (rapamycin) has been sparsely reported in the treatment of pediatric ulcerative colitis (PUC). Mucosal healing has not been examined in responders to the drug. We describe a case of infliximab refractory PUC where rapamycin induced sustained clinical remission along with mucosal healing. We conclude that rapamycin should be positioned into the expanding treatment repertoire of PUC.
Included in
Digestive System Diseases Commons, Gastroenterology Commons, Medical Sciences Commons, Pediatrics Commons